Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
7(100.0%)
7Total
Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06928363Phase 1Not Yet Recruiting

A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.

Role: lead

NCT06518876Phase 1Not Yet Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

Role: lead

NCT06445803Phase 1Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Role: collaborator

NCT06223646Phase 1Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT04714827Phase 1Unknown

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT04715217Phase 1Unknown

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Role: collaborator

NCT06175780Phase 1Unknown

Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Role: lead

All 7 trials loaded